Jenburkt Pharmaceuticals Board of Directors
Get the latest insights into the leadership at Jenburkt Pharmaceuticals. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Ashish U Bhuta | Chairman & Managing Director |
| Mr. Dilip H Bhuta | WholeTime Director & CFO |
| Mrs. Hina R Mehta | Ind. Non-Executive Director |
| Mr. Sumit A Thakkar | Ind. Non-Executive Director |
| Mr. Krishnan Subharaman | Ind. Non-Executive Director |
| Mr. Pankaj A Dantwala | Ind. Non-Executive Director |
Jenburkt Pharmaceuticals Share price
JENBURPH
1174
14.25 (-1.20%)Last updated on 4 Sep, 2025 | 15:28 IST
BUYSELL
Today's High
1199.90
Today's Low
1150.30
52 Week Low
920.20
52 Week High
1410.00
The current prices are delayed, login to your account for live prices
LoginJenburkt Pharmaceuticals FAQs
The board at Jenburkt Pharmaceuticals consists of experienced professionals, including Mr. Ashish U Bhuta , Mr. Dilip H Bhuta , and others, overseeing the company’s strategic and corporate governance.
Directors at Jenburkt Pharmaceuticals are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Ashish U Bhuta is the current chairman at Jenburkt Pharmaceuticals.
Executive directors at Jenburkt Pharmaceuticals are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Jenburkt Pharmaceuticals adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Jenburkt Pharmaceuticals, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.